Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04566952 2020-10-30

ANLOLA

Phase 2 Unknown

68 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04124731 2019-10-11

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Phase 2 Unknown

98 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02605811 2019-03-28

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Phase 2 Unknown

426 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Small Cell Lung Carcinoma

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT01791387 2015-02-03

DILIGENCE-1

Phase 2 Unknown

30 enrolled

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT01556815 2012-04-25

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Phase 2 Unknown

40 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT01533324 2012-02-15

S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

32 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Liver Diseases

NCT01216371 2012-02-13

SMAT

Phase 2 Unknown

60 enrolled

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00908336 2009-05-25

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Phase 2 Unknown

70 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00905983 2009-05-21

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Unknown

48 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00894569 2009-05-14

PACET-CUP

Phase 2 Unknown

150 enrolled

Tumor-Agnostic

Carcinoma, Neoplasms, Unknown Primary

Clinical Trials

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

DUNCAN

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

TIDE-A

AVANIRA3

ANLOLA

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

DILIGENCE-1

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

SMAT

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

PACET-CUP